Recent Updates
Recently added Catalysts

Alitretinoin

Phase 2

Sarcoma, Kaposi | Small molecule | Oncology |Ligand Pharmaceuticals Incorporated|Last Updated: Jun 24, 2005

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment27
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002188A Study of ALRT1057 in Patients With AIDS-Related Kaposi's SarcomaPHASE2 COMPLETED 27 - -Jun 24, 2005 -
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
AlitretinoinDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria Patients must have: * HIV positive status and histologic confirmation of KS. * CD4 count \> 200 mm3 (required of one-half of patients). * Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting criteria for "indicator" lesions. * Acceptable organ syste...

Unlock Eligibility Criteria